Literature DB >> 25004821

Predicting when biliary excretion of parent drug is a major route of elimination in humans.

Chelsea M Hosey1, Fabio Broccatelli, Leslie Z Benet.   

Abstract

Biliary excretion is an important route of elimination for many drugs, yet measuring the extent of biliary elimination is difficult, invasive, and variable. Biliary elimination has been quantified for few drugs with a limited number of subjects, who are often diseased patients. An accurate prediction of which drugs or new molecular entities are significantly eliminated in the bile may predict potential drug-drug interactions, pharmacokinetics, and toxicities. The Biopharmaceutics Drug Disposition Classification System (BDDCS) characterizes significant routes of drug elimination, identifies potential transporter effects, and is useful in understanding drug-drug interactions. Class 1 and 2 drugs are primarily eliminated in humans via metabolism and will not exhibit significant biliary excretion of parent compound. In contrast, class 3 and 4 drugs are primarily excreted unchanged in the urine or bile. Here, we characterize the significant elimination route of 105 orally administered class 3 and 4 drugs. We introduce and validate a novel model, predicting significant biliary elimination using a simple classification scheme. The model is accurate for 83% of 30 drugs collected after model development. The model corroborates the observation that biliarily eliminated drugs have high molecular weights, while demonstrating the necessity of considering route of administration and extent of metabolism when predicting biliary excretion. Interestingly, a predictor of potential metabolism significantly improves predictions of major elimination routes of poorly metabolized drugs. This model successfully predicts the major elimination route for poorly permeable/poorly metabolized drugs and may be applied prior to human dosing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25004821      PMCID: PMC4147063          DOI: 10.1208/s12248-014-9636-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  57 in total

1.  Utility of metabolic stability screening: comparison of in vitro and in vivo clearance.

Authors:  S E Clarke; P Jeffrey
Journal:  Xenobiotica       Date:  2001 Aug-Sep       Impact factor: 1.908

2.  Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.

Authors:  Wakaba Yamashiro; Kazuya Maeda; Masakazu Hirouchi; Yasuhisa Adachi; Zhuohan Hu; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-04-19       Impact factor: 3.922

3.  Transport characteristics of candesartan in human intestinal Caco-2 cell line.

Authors:  Lingjie Zhou; Xiaoping Chen; Yuanqing Gu; Jianying Liang
Journal:  Biopharm Drug Dispos       Date:  2009-07       Impact factor: 1.627

Review 4.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

5.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

6.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

Review 7.  The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Authors:  Leslie Z Benet
Journal:  J Pharm Sci       Date:  2012-11-12       Impact factor: 3.534

Review 8.  Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Authors:  Collen M Masimirembwa; Ulf Bredberg; Tommy B Andersson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Authors:  Koji Abe; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-12-15       Impact factor: 3.922

Review 10.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

View more
  9 in total

Review 1.  BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Authors:  Chelsea M Hosey; Rosa Chan; Leslie Z Benet
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

2.  Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.

Authors:  Chelsea M Hosey; Leslie Z Benet
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

3.  Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016.

Authors:  Anitha Saravanakumar; Armin Sadighi; Rachel Ryu; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 4.  Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.

Authors:  Gian P Camenisch
Journal:  Pharm Res       Date:  2016-07-20       Impact factor: 4.200

Review 5.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

6.  Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.

Authors:  Zhengyuan Zhou; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioorg Med Chem       Date:  2020-07-09       Impact factor: 3.641

7.  Potential premalignant status of gastric portion excluded after Roux en-Y gastric bypass in obese women: A pilot study.

Authors:  Graziela Rosa Ravacci; Robson Ishida; Raquel Suzana Torrinhas; Priscila Sala; Natasha Mendonça Machado; Danielle Cristina Fonseca; Gisele André Baptista Canuto; Ernani Pinto; Viviane Nascimento; Marina Franco Maggi Tavares; Paulo Sakai; Joel Faintuch; Marco Aurelio Santo; Eduardo Guimarães Hourneaux Moura; Ricardo Artigiani Neto; Angela Flávia Logullo; Dan Linetzky Waitzberg
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

Review 8.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

9.  Use of in-silico assays to characterize the ADMET profile and identify potential therapeutic targets of fusarochromanone, a novel anti-cancer agent.

Authors:  Madison Wynne El-Saadi; Tara Williams-Hart; Brian A Salvatore; Elahe Mahdavian
Journal:  In Silico Pharmacol       Date:  2015-06-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.